Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
6.12-------------crazy!!! porque???
I have COVID--- 2nd month... and a ton of DCTH stock.
DCTH stock price--- OY OY OY...
what? why? when?
I gotta call Toronto!!!!!!!!!!!!!!!!!
Have had Covid now all of Jan...
UGH. TY, Neal
Bought a bunch today. Got way too cheap.
???????????????????? wtf
Gotta call Gil in TO.
Thanks! We are loaded--- !
I will call Toronto!
Best, Neal, NY NY
Free money Neal. Snacked hard on the December feed.
Bring on 2022. We will obliterate $25 in the new year. Mark my words. Will be be breathe taking when once they let her go.
Nice close to end the year. Possible triple bottom at then end of a correction? Might just be about ready.
Happy New Year
GL
7.50!--- why??? PT is $25... wtf.
wtf... gotta call Toronto. :(
PT $25 and more if all goes as planned
Holding a lot, hoping, waiting...
It should be a BUY.
Yeah, seems like data is still good.
Lol, what’s going on here???
10.5 now support. Lets GO !!
Another crack at that 10.5 wall coming up.
Making another attempt to get loose...
GL
up today... $10 now.
should rise now into Fall presentation in Europe...
Excellent. I think it was a waste of time talking to management before this latest generation, now a bit better. I am not 100 percent confident, but risk/reward is good
they say all is OK...
we BUY
need info...
Getting excited for the coming weeks
GL
$10... Beast mode about to be activated
No reason to my knowledge to discount all the insider support
All OK it seems and Sept conf in Europe with Phase III reported... Zager.
This is too low here. BUY.
Financing ahead should not be onerous.
CEO is doing well they say.
You'd be kicking yourself for a long time to come if your weren't feasting on this level
In a few months will look back an laugh it was below $10
GL
I am buying DCTH!!!!!!!!!!!
Looking interesting again here
Looks nice heading into next week
Looks like show time...
GL
Set to join the russell microcap index!!!
With these kind of results I think Delcath should start pursuing sale to a bigger device or oncology company soon. Going alone would be foolish, a bigger device or oncology company can easily make this standard of care, would be harder for a small company to do the same.
I like the idea of a $600 market cap goal, either 2021 or 2022. I would factor in 15 million shares outstanding, but $40 works for me, I have a good position I hope to sell none before $18
Today's new data is striking, 44% vs 17% improvement for best overall response not just Delcath vs placebo, but Delcath vs "best alternative care". Not many FDA approved treatments can boast such improvements over best alternate care, many are approved based on improvements over placebo.
as you know well, co was once $600 million...
Filterthenoise can be discounted I am sad to say...
"filter"(out) filter is right! :)
Creeping... Should get fun in the coming weeks
Followers
|
497
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50157
|
Created
|
05/11/05
|
Type
|
Free
|
Moderators |
In December 2018, Delcath entered into a License Agreement with medac GmbH for the commercialization of the CHEMOSAT® system in Europe. Under the terms of the medac License, medac has the exclusive right to sell and market CHEMOSAT® in all member states of the EU, Norway, Liechtenstein, Switzerland, and the United Kingdom.
Since launching CHEMOSAT® in Europe, over 750 commercial treatments have been performed at over 25 European cancer centers. Physicians in Europe have used CHEMOSAT® to treat patients with a variety of cancers in the liver, primarily ocular melanoma liver metastases, and other tumor types including cutaneous melanoma, hepatocellular carcinoma, cholangiocarcinoma, and liver metastases from colorectal cancer, breast, pancreatic and neuroendocrine.Split # | Date | Ratio |
1 | April 9, 2014 | 1:16 |
2 | July 21, 2016 | 1:16 |
3 | November 6, 2017 | 1:350 |
4 | May 2, 2018 | 1:500 |
5 | December 24, 2019 | 1:700 |
Common Shares Authorized: | 1,000,000,000 |
Common Shares Outstanding: | 70,056 |
Preferred Shares Authorized: | 10,000,000 |
Preferred Shares Outstanding: | 41,447 |
Warrants: | 29 | ($42; exp 2/2020 - 10/2021) |
2019 Warrants: | 1,826,579 | ($23.04; exp 12/2024) |
Options: | 1,640 | |
Total Warrants/Options: | 1,828,248 |
Preferred Stock: | 1,799,093 |
Convertible Notes: | 63,493 |
Total Reserved: | 1,862,586 |
Jennifer K. Simpson, Ph.D. | : 2,965 |
John Purpura, M.S. | : 2,830 |
William D. Rueckert | : 2,619 |
Roger G. Stoll, Ph.D. | : 4,047 |
Marco Taglietti, M.D. | : 2,606 |
Total Shares | : 21,459 |
Altium Capital Management L.P. | : 7,204 |
Rosalind Master Fund L.P. | : 7,024 |
Hudson Bay Master Fund Ltd. | : 7,024 |
Total Shares | : 21,612 |
45 Shareholders (est.) | : 26,985 |
Company Website: Delcath Systems, Inc. | Stock and Financial Website: OTC Marketplace |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |